RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

They could also offer a more potent option to conventional flu shots, according to mRNA vaccine developers. Current flu vaccines generally offer only around 40% to 60% protective efficacy ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...

We're learning more about a massive artificial intelligence infrastructure bill announced Tuesday by President Donald Trump.

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...